Pharma's Almanac

3294 Articles Available

1 138

Endpoints

MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, Has Been Met, Confirming Previously Published Activity

PR-M05-19-NI-065

Clinical Data

New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol

PR-M05-19-NI-064

Series A Financing

Syncona founds Quell Therapeutics with £35 million Series A Financing

PR-M05-19-NI-063

Financing

Schrödinger Announces Close of Latest Financing, Raising a Total of $110 Million

PR-M05-19-NI-062

Phase I Study

Painting Tumors Is a Promising Approach to Improve Surgical Outcomes

PAO-M05-19-NI-024

FDA Approval

Second Generation On-the-Go ECG Device Gets FDA Approval

PAO-M05-19-NI-023

Drug Design

Janssen, Iktos Collaborate on In Silico Drug Design

PAO-M05-19-NI-022

M&A

Vertiflex Acquired by Boston Scientific

PAO-M05-19-NI-021

Biosimilar

Successful Results Reported for Another Rituximab Biosimilar

PAO-M05-19-NI-020

Funding

Philogen Raises $70 Million

PAO-M05-19-NI-019

Divestiture

Takeda Slimming Down

PAO-M05-19-NI-018

Drug Pricing

New Regulation Requires Pricing Info in TV Pharma Ads

PAO-M05-19-NI-017

Financing

Actuate Therapeutics Completes $21.7 Million Series B Financing

PR-M05-19-NI-061

Clinical Trial Data

Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

PR-M05-19-NI-060

Leadership

DBV Technologies Announces Departure of Deputy CEO David Schilansky

PR-M05-19-NI-059

Collaboration

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

PR-M05-19-NI-058

FDA Approval

FDA Approves Venetoclax for CLL and SLL

PR-M05-19-NI-057

Legal

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

PR-M05-19-NI-056

Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis

PR-M05-19-NI-055

Announcement

AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer

PR-M05-19-NI-054

Announcement

Nestlé Enters into Exclusive Negotiations to Sell Nestlé Skin Health to a Consortium Led by EQT and ADIA

PR-M05-19-NI-053

Antibiotics

Ginkgo Bioworks Acquires Warp Drive Bio's Genome Mining Platform for Discovery and Development of Novel Classes of Antibiotics

PR-M05-19-NI-052

M&A

Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK

PR-M05-19-NI-051

FDA Approval

Genentech Announces FDA Approval for Venclexta Plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia

PR-M05-19-NI-050

1 138

»